- Raised funding round, Oct 2014
About
GlaucoPharm is the developer of TG-46, a topical treatment for glaucoma. TG-46 is useful for the treatment of diseases modulated by the pyrimidinergic receptor P2Y6. The P2Y6 receptor has been identified in trabecular meshwork (TM) cells, an area of tissue in the eye that is responsible for draining the aqueous humor. The companys product shows evidence of a novel mechanism of action, making it a potential alternative to first-line drugs. It binds tightly and selectively to P2Y6R and reduces intraocular pressure by up to 45%, compared to the 25% to 35% reduction produced by most drugs on the market. TG-46 is highly stable chemically and enzymatically, with a duration of action longer than 3.5 hours. Its synthesis is facile and results in good yields, and preliminary data show that it causes fewer side effects than most standard treatments.
Funding history · 1 round · — total
Q&A
- What is GlaucoPharm's primary focus?
- GlaucoPharm is focused on developing TG-46, a topical treatment for glaucoma.
- When was GlaucoPharm founded?
- GlaucoPharm was founded in August 2013.
- What is the status of GlaucoPharm?
- GlaucoPharm is currently inactive, having ceased operations in April 2019.
- How many employees did GlaucoPharm have?
- GlaucoPharm had 1-10 employees.
- What is the mechanism of action for GlaucoPharm's product, TG-46?
- TG-46 is a treatment for diseases modulated by the pyrimidinergic receptor P2Y6, binding selectively to P2Y6R to reduce intraocular pressure.
- What is the reported efficacy of TG-46 in reducing intraocular pressure?
- TG-46 has shown to reduce intraocular pressure by up to 45%, which is higher than the 25% to 35% reduction typically produced by most drugs on the market.
- When did GlaucoPharm receive its last known funding?
- GlaucoPharm received funding in October 2014 from Abital and Office of the Chief Scientist.
- What is GlaucoPharm's current product stage?
- GlaucoPharm's product, TG-46, is in the R&D stage.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2013-8 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Apr 2019 ceased to operate |